CDC’s Role in Safe Injection Practices
CDC works with numerous partners to conduct a range of activities to improve injection safety and prevent transmission of bloodborne pathogens and other infectious diseases. Below are some of CDC’s current injection safety activities.
- Promotion of Safe Injection Practices
- Development of Infection Control Guidelines
- Improved Basic Infection Control through Collaborations with CMS
- Improved Safety through Collaborations with FDA
- Improved Healthcare Personnel Protections from Sharps Injuries
- Responding to Outbreaks in Healthcare Settings
- Identification and Promotion of Best Practices for Patient Notification
- Efforts to Improve Injection Safety through Collaborations with Industry
- Improved Capacity in State Health Departments
- Expansion of the HHS Action Plan to Prevent HAIs in Outpatient Healthcare Settings
- Identification of Drug Diversion as an Infection Risk
CDC is collaborating with the Safe Injection Practices Coalition (SIPC) to develop and implement an educational campaign to promote safe injection practices by raising awareness among patients and healthcare providers about safe injection practices.
For more information visit the One & Only Campaign.
CDC and the Healthcare Infection Control Practices Advisory Committee (HICPAC), a federal advisory committee, developed recommendations on Safe Injection Practices which are applicable in all healthcare settings. These recommendations are part of Standard Precautions and can be found in the 2007 Guideline for Isolation Precautions. CDC and HICPAC are in the process of further developing documents specifically targeting infection control practices in outpatient healthcare settings.
CDC is improving basic infection control practices and safe injection practices through collaborations with the Centers for Medicaid and Medicare Services (CMS) to enhance survey and oversight capacity of non-acute healthcare settings.
CDC is collaborating with the Food and Drug Administration (FDA) to address issues associated with medication packaging, labeling and instructions for safe use as well as to promote safe injection practices and prevent the misuse of injectable medications, injection equipment, and related devices.
CDC has developed guidance, toolkits and surveillance packages aimed at protecting healthcare personnel from blood and body fluid exposures and sharps injuries.
CDC hosted a meeting to discuss and obtain input on the ethical and communication issues surrounding patient notification when a serious lapse in infection control (e.g., syringe reuse) has been identified. To supplement the input obtained at the meeting, CDC conducted a series of focus groups to further evaluate patient notification practices. CDC is in the process of further developing and disseminating these investigation, risk assessment and patient notification tools.
CDC is working to promote innovation in product development and identify education and marketing improvements through industry partner meetings in May 2010 with leaders from injection equipment and medication industries and other partners.
CDC is building infrastructure and capacity in state health departments to address healthcare-associated infection and patient safety issues through Healthcare-Associated Infection (HAI) Recovery Act Funding.
CDC collaborated closely with HHS, AHRQ, CMS, and other federal agencies to expand the HHS Action Plan to Prevent HAIs to include ambulatory surgical centers and hemodialysis centers. CDC continues to play a lead role as these modules are developed, helping focus attention on the need to assure that safe injection and other basic infection control standards are met in all settings where healthcare is delivered.
CDC and health departments continue to investigate and identify outbreaks stemming from drug diversion activities involving healthcare providers.